Cumberland Pharmaceu (CPIX) Stock Price, Quote & News

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 255 0068

Fax: 615 255 0094

Website: www.cumberlandpharma.com

Address:

1600 West End Avenue, Suite 1300, Nashville, United States

haha1978 Jan. 8 at 7:36 PM

$CPIX This is also known as the NY traders who trained my trader friends and me said decades ago. Its a red bar sandwich which is basically after 2 or 3 days of an up day on the daily chart you will get a light volume red day the next day. Then the next day after the red day is another green candle. That the definition of a red bar sandwich or a red bar between two green candles. The other aspect is once it hits that black line it will bounce up.

0 · Reply

haha1978 Jan. 8 at 7:20 PM

$CPIX Here is another chart perspective. The daily chart and look. A few days ago it was 4.00 at an RSI at 68. Well today we are around $4.80 at an RSI of 70. Basically, no change in RSI yet we are 80 cents higher. The Bollinger bands are starting to tighten in the next 3 to 10 trading days it will narrow and hints at a move coming up or down but due to the weekly chart having its first candle up it hints at at least a 2nd green weekly candle and/or a 3rd weekly green candle so odds are its going to retest 6.00.

0 · Reply

haha1978 Jan. 8 at 5:42 PM

$CPIX All that matters is the weekly prints on the Bollinger band the green line or above 4.50 indicating break out into the new channel. Looks like we are good. This is low volume pull back so it wont last. Looking forward to next week. We still most likely have 1 or maybe 2 more weeks up. Goodluck longs.

0 · Reply

WesleyVanguard3 Jan. 8 at 4:59 PM

$CPIX This stock is a game changer. Add before this 🚀takes off I got a real good feeling about this one.

0 · Reply

Diiiii Jan. 8 at 2:30 PM

$CPIX worth a look 🚀 Caldolor's J1741 code just got official CMS reimbursement pricing 💉 That means it's now firmly embedded in the national opioid crisis strategy — a non-opioid option backed by the government, with sales poised to build naturally. Yet with a market cap still under $100M, this institutional tailwind hasn't fully priced in yet... 📈 Add in the bigger upside potential from Ifetroban in the pipeline (positive Phase II data in portopulmonary hypertension) Feels like we're still in that early, "quiet before the move" sweet spot. Might regret sleeping on this one 😏 #CPIX #Biotech #OpioidAlternative

0 · Reply

Diiiii Jan. 8 at 3:39 AM

$CPIX "Opioid alternatives" = massive US policy push, everyone knows the opportunity is HUGE 💊 But here's the thing - actually playing it? Trickier than you'd think. I took a swing at $TNXP myself back in the day... whiffed on that one 😅 BUT here's where it gets spicy 🌶️ - for a low float/low marketcap like this, you don't need the whole pie. Just catching CRUMBS from that opioid alternative wave could send this thing parabolic 🚀 And check the chart since last month - looks like it's already telling that exact story! 📈✨

1 · Reply

BioResearcher Jan. 8 at 2:57 AM

$CPIX It is like all these values is packed into a tiny dot in Big Bang, due to CPIX 's invisibility to Wall Street. But soon, it will explode and expand into the Universe that we know and love.

0 · Reply

Diiiii Jan. 8 at 2:44 AM

$CPIX @BioResearcher @jimmy18000 @haha1978 @cninc Every post here is interesting in its own way. IMO, CALDOLOR getting CMS separate reimbursement status for NON-OPIOID PAIN that is a hidden big positive catalyst for this tiny company. Sure, it's not as flashy as the big Ifetroban pipeline stories everyone's hyping—more like a buried headline nobody's talking about. BUT HERE'S THE THING: with this low float + low market cap, if ANYONE's thesis hits—yours, mine, anyone's—we're looking at multi-bagger territory! 🚀 The chart shape and volume look like they're about to explode.

1 · Reply

BioResearcher Jan. 7 at 9:55 PM

$CPIX Best of all the current revenue of $40 mils from 6 approved drug should put the bottom of this stock at least $ 5 per share. (2 times revenue by standard) (without considering any other potentials: cancers, DMD cardio, IPF, SSC )

0 · Reply

jimmy18000 Jan. 7 at 9:36 PM

$CPIX @Diiiii phase 2 trial results due anytime now (Q1) for Idiopathic Pulmonary Fibrosis with a multi billion market, could be an icing on the cake of DMD end of phase 2 FDA meeting results and CA indication to prevent metastasis updates. I’m long $CAPR and that has gave me fortune and with CPIX 70 mil MC, we have great potential ahead. A lot of catalysts in the short term this Q.

0 · Reply

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

Nov 4, 2025, 6:06 PM EST - 2 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 5:00 PM EST - 2 months ago

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Oct 28, 2025, 4:05 PM EDT - 2 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

Oct 20, 2025, 9:05 AM EDT - 2 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

RDHL

Oct 20, 2025, 9:00 AM EDT - 2 months ago

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Oct 13, 2025, 9:05 AM EDT - 3 months ago

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

Oct 1, 2025, 9:05 AM EDT - 3 months ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

Sep 29, 2025, 9:05 AM EDT - 3 months ago

TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

Aug 6, 2025, 1:52 AM EDT - 5 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 5 months ago

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Aug 4, 2025, 9:05 AM EDT - 5 months ago

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Jul 29, 2025, 4:05 PM EDT - 5 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

Jun 23, 2025, 9:05 AM EDT - 7 months ago

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

May 27, 2025, 4:05 PM EDT - 8 months ago

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

May 13, 2025, 4:05 PM EDT - 8 months ago

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

May 10, 2025, 4:23 AM EDT - 8 months ago

Cumberland Pharmaceuticals, Inc. (CPIX) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 8 months ago

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Apr 29, 2025, 4:05 PM EDT - 9 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

Mar 19, 2025, 4:05 PM EDT - 10 months ago

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Mar 4, 2025, 7:14 PM EST - 11 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:05 PM EST - 11 months ago

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Feb 25, 2025, 4:05 PM EST - 11 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Feb 18, 2025, 7:30 AM EST - 11 months ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Feb 4, 2025, 1:31 PM EST - 1 year ago

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Feb 4, 2025, 7:30 AM EST - 1 year ago

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Dec 10, 2024, 12:08 PM EST - 1 year ago

Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?

Dec 9, 2024, 4:05 PM EST - 1 year ago

FDA APPROVES ACETADOTE® sNDA

Nov 9, 2024, 1:17 PM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Nov 6, 2024, 5:21 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Nov 5, 2024, 4:05 PM EST - 1 year ago

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

Oct 31, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

Aug 11, 2024, 12:47 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024

Jul 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS

May 11, 2024, 11:51 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Apr 2, 2024, 4:05 PM EDT - 1 year ago

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Mar 5, 2024, 10:06 PM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Nov 11, 2023, 8:17 AM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

Oct 10, 2023, 4:05 PM EDT - 2 years ago

NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE

Aug 12, 2023, 4:21 AM EDT - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

Aug 1, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS

haha1978 Jan. 8 at 7:36 PM

0 · Reply

haha1978 Jan. 8 at 7:20 PM

0 · Reply

haha1978 Jan. 8 at 5:42 PM

0 · Reply

WesleyVanguard3 Jan. 8 at 4:59 PM

$CPIX This stock is a game changer. Add before this 🚀takes off I got a real good feeling about this one.

0 · Reply

Diiiii Jan. 8 at 2:30 PM

0 · Reply

Diiiii Jan. 8 at 3:39 AM

1 · Reply

BioResearcher Jan. 8 at 2:57 AM

$CPIX It is like all these values is packed into a tiny dot in Big Bang, due to CPIX 's invisibility to Wall Street. But soon, it will explode and expand into the Universe that we know and love.

0 · Reply

Diiiii Jan. 8 at 2:44 AM

1 · Reply

BioResearcher Jan. 7 at 9:55 PM

0 · Reply

jimmy18000 Jan. 7 at 9:36 PM

0 · Reply

BioResearcher Jan. 7 at 9:03 PM

$CPIX Volume is again unusually heavy today : 360K shares! Institutions have started to accumulate ????

0 · Reply

BioResearcher Jan. 7 at 8:47 PM

$CPIX Ifetroban cannot replace Keytruda, BUT, it will help Keytruda work much better. Cancer patients need multiple drugs to treat their cancers, one drug is not enough because there are many pathways for cancer cells to grow and spread.

0 · Reply

cninc Jan. 7 at 8:05 PM

$CPIX looks like everything is popping, be nice to close over 5.60 mark.

1 · Reply

Diiiii Jan. 7 at 7:46 PM

$CPIX All these die-hard watchers hyping Ifetroban's cancer metastasis suppression like it's the next big cure... is it really THAT game-changing? Honestly, jury's still out. Feels more like the buzz is from that non-opioid alternative vibe with CMS news kicking in. But damn, zoom out on the short-term chart, long-term setup, volume spiking – it's screaming early-stage breakout vibes. Something massive could be brewing here... 👀🚀

2 · Reply

haha1978 Jan. 7 at 4:51 PM

$CPIX Probably more than the offensive cancer treatments that in general dont do much in terms of extending time of life.

0 · Reply

haha1978 Jan. 7 at 4:50 PM

$CPIX Whats crazy is ifetroban will complement existing PD-1 immunotherapy drugs making them all more effective. This will drug is definitely going to get acquired at some point. The cancer benefit is equal to cancer treatments. If you stop cancer from spreading so it stays local you can live with cancer for a long time. How much is that worth?

2 · Reply

BioResearcher Jan. 7 at 3:15 PM

$CPIX WOW, I just found another peer-reviewed study about thyroid cancer metastasis and TXA2 inhibitors Ifetroban: (2025) "..Thus, targeting COX-1/TXA2 signaling may improve the efficacy of PD-L1 immunotherapy by disrupting this protective shield. Given unwanted gastrointestinal side effects of aspirin, a potent and selective TXA2 receptor antagonist, Ifetroban, has been re-evaluated for the treatment of metastatic cancer and is currently under Phase II clinical trial (NCT03694249) (59)."

1 · Reply

BioResearcher Jan. 7 at 2:26 PM

$CPIX What I like about the recent SP rise is: - There has been no company PR to trigger it, - No analysts upgrade (no analysts follow this stock) - no company road show, fireside chats... The rise started with heavy volume right after the researchers from U. of Miss reported Ifetroban breakthrough finding in the San Antonio Breast Cancer Symposium 2025 - December. So, the recent buying is likely from the scientists or their associated groups. Which is super bullish, because they are the experts in the field, and they know the finding has great data.

0 · Reply

BioResearcher Jan. 7 at 1:10 PM

$CPIX For new investors: In an 6 - year long study, University of Mississippi and U. of Indiana joined hands to research Ifetroban on cancers treatment especially TNBC. The finding is a breakthrough in stop cancers from spreading.

0 · Reply

2pumps1dump Jan. 7 at 12:36 PM

$CPIX

0 · Reply

haha1978 Jan. 7 at 6:54 AM

$CPIX Plus volume precedes price movement which happened and if you look at the shorter term it was a cup and handle and we were in the handle the last 2 weeks and its over now. Next flagpole and flag pattern is forming now as it goes higher.

0 · Reply

haha1978 Jan. 7 at 6:52 AM

$CPIX So the second wave just started and it was actually the weekly chart that trumped the daily chart. The daily chart now moved into an uptrend thanks most in part to the weekly. The weekly chart has no resistance till 6 to 6.30 and if we break 6.30 this will go into a new channeled range maybe to 10. Its riding the Bollinger band which is what is required for breakouts or pullbacks and the MACD just crossed over so we have probably 2 or 3 weeks of upside. Its primed and looks like it just starting. The RSI is only 63 not even close to over bought yet. I would love to see the weekly RSI get into 80 over the next 3 weeks. Dont forget we had 11 months of consolidation since Febuary. I highlighted the major signs i look for in charting. This is also above the 50 and 200 DMA. Hope you all had a perfect day.

1 · Reply

Market Cap	59.53M
Revenue (ttm)	37.87M
Net Income (ttm)	-6.48M
EPS (ttm)	N/A
PE Ratio	49.75
Forward PE	N/A
Profit Margin	-17.11%
Debt to Equity Ratio	0.20

Volume	199,800
Avg Vol	158,406
Day's Range	N/A - N/A
Shares Out	14.96M
Stochastic %K	88%
Beta	-0.53
Analysts	Strong Buy
Price Target	$8.50